Introduction 23
Streptococcus agalactiae, often referred to as Group B Streptococcus (GBS), is a gram-positive 24 bacterium found in the rectum and vagina of approximately 25% of pregnant women (1) . While 25 GBS is an asymptomatic colonizer of most healthy adults, it can cause severe infections in 26 neonates, including sepsis, pneumonia, and meningitis (2, 3). GBS early onset disease (EOD) 27 are infections that occur in the first week of life and can be extremely dangerous to the newborn; 28 EOD occurred in 3 per 1000 live births and was associated with a high mortality rate prior to the 29 1990s (4). Due to the high neonatal mortality rate caused by GBS infections, the Center for 30
Disease Control (CDC) implemented a universal guideline in 1996 with recommended screening 31 of all pregnant women at 35-37 weeks of gestation and administration of intrapartum 32 prophylaxis (IAP) in pregnant women that tested positive (1, 5) . 33
Despite these guidelines, infection with S. agalactiae remains a leading cause of morbidity in 34 neonates born in the United States and therefore the implementation of more rapid and sensitive 35 screening techniques for GBS detection may further reduce transmission of GBS infection 36 intrapartum (1, 6, 7) . The current gold standard for GBS detection is enrichment of the primary 37 specimen, a vaginal-rectal swab, followed by subculture onto a blood agar plate with phenotypic 38 characterization (1) . This gold standard method has an extensive turnaround time and GBS 39 colonization sensitivity is only 54-87% (8, 9). Furthermore, bacterial culture requires an 40 experienced technician to further identify and test characteristics of GBS such agglutination and 41 beta hemolysis (1) . 42
Although culture remains the gold standard in GBS diagnostics, the 2010 CDC revision for GBS 43 testing allows for nucleic acid amplification tests (NAAT) such as polymerase chain reaction 44 (PCR) as an option for GBS testing (1) . A PCR method based on amplification of the CAMP 45 factor encoding gene (cfb), a fragment that is present in nearly all GBS strains, was developed by 46 Ke et al. (3) 
GBS LB Assay 66
All enriched samples were first tested on the GeneXpert Dx system using the Xpert® GBS LB 67 Assay according to the manufacturer's instructions. Briefly, the LIM broth enriched samples 68 were inverted 3 times and a sterile swab was immersed into the LIM broth enriched samples. 69
This swab was immediately inserted into the sample chamber in the Xpert ® GBS LB cartridge 70 and run on the GeneXpert Dx System. 71
GenePOC™ GBS LB Assay 72
Following completion on the GeneXpert Dx system, the same LIM broth enriched specimens 73 were tested on the GenePOC™ system according to the manufacturer's instructions. Briefly, the 74 LIM broth enriched samples were vortexed for 15 seconds and diluted into the diluent buffer. 75
The diluted samples were vortexed for another 15 seconds and loaded into GenePOC™ GBS LB 76 PIE and run on the revogene. 77
Bacterial Culture Testing 78
Reference culture testing was performed on all discordant samples in accordance with published 79 CDC guidelines. Briefly, the LIM broth enriched samples were sub-cultured onto blood agar 80 plates and incubated for 18 to 24h at 37°C in 5% CO 2 . The blood agar plates without any 81 colonies observed at 24h were re-incubated for an additional 24h. If after 48h no colonies 82 formed, the culture was deemed negative. Any suspected colonies were identified via matrixassisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS Concordant results between the assays were recorded, and no additional testing was performed. 92
Discordant results between the initial tests were resolved in two ways: repeating the tests on both 93 instrument platforms and culturing the enriched specimens to check for GBS presence. Results 94 from these additional tests were compared against two definitions of true positivity: 3 of 4 95 molecular tests yielding a positive GBS result or GBS presence in culture. These definitions will 96 be referred to as standard A and B, respectively. 97
Results

98
From the 250 total samples tested, 242 samples were concordant (96.8%), and eight samples 99 were discrepant (3.2%) between the two molecular assays. Among the eight discrepant results, 100 seven specimens tested negative by GeneXpert GenePOC ™ instrument during this study was that we were unable to readily view Ct values, 137 which could have been useful for troubleshooting and discrepancy analysis; we were notified 138 that this feature will be made available in the future. A major advantage of GenePOC ™ was the 139 higher sensitivity, although there were more false positives based on our two standards of true 140 positivity. It is noteworthy to highlight the single discrepant sample that resulted in GBS-141 negative GeneXpert ® results compared to GBS-positive GenePOC ™ and culture results (Table  142 1A). Both the GeneXpert ® and the GenePOC ™ GBS assays' primers and probes detect a target 143 within or adjacent to the CAMP factor encoding gene (cfb) of S. agalactiae (4, 12, 13) . This cfbgene is noted to be present in almost all group B streptococci, yet recent findings have described 145 cases of cfb-negative isolates that were missed by the GeneXpert ® system (15, 16 
